For example, patients with non-small cell lung cancer with an epidermal growth factor receptor (EGFR) mutation exhibit enhanced responses to targeted therapy even at locally advanced stages.(11) Distinct molecular markers and corresponding therapies have also been associated with improved long-term survival in patients with breast cancer, colon cancer, melanoma, and other cancers. This evidence concerns the gene EGFR and non-small cell lung carcinoma.